MedTrace Logo

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.

Conditions

  • Breast Cancer
  • Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

Interventions

DRUG

Tucatinib

taken orally

DRUG

Eribulin

taknen intravenously

DRUG

Trastuzumab

taken intravenously

Sponsors & Collaborators

  • Criterium, Inc.

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-30
Primary Completion
2027-06-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05458674 on ClinicalTrials.gov